Eddingpharm to Market AFib Drug in China for Cardiome

Eddingpharm, a company that in-licenses drugs for China marketing, secured greater China rights to Brinavess™ from Cardiome Pharma of Canada. Brinavess is a treatment for recent onset atrial fibrillation. Eddingpharm paid $1 million upfront and will make up to $3 million in regulatory milestones. It will also be responsible for meeting China regulatory requirements, including clinical trials, and agreed to undisclosed sales targets for Brinavess. More details.... Stock Symbols: (NSDQ: CRME; TSX: COM) Share this with colleagues: // //